08.17.18
Mundipharma and Helsinn Group signed a licensing and distribution agreement for the anti-emetic agent Aloxi in Vietnam, extending an international collaboration. Aloxi (palonosetron hydrochloride), a 5-HT3 receptor antagonist, has been approved in Vietnam for the treatment of Chemotherapy-Induced Nausea and Vomiting (CINV), one of the most common side effects of cancer chemotherapy.
"This important extension of our portfolio in Vietnam offers relief to patients suffering from the side effects of chemotherapy and enables patients and healthcare providers to benefit from our expertise in this area," said Raman Singh, chief executive officer, Mundipharma.
Riccardo Braglia, vice chairman and chief executive officer, Helsinn Group, said, "Helsinn and Mundipharma have an effective, longstanding partnership and Mundipharma successfully markets, promotes and distributes a number of our products across a range of territories. We're delighted to be able to extend this relationship through this agreement."
"This important extension of our portfolio in Vietnam offers relief to patients suffering from the side effects of chemotherapy and enables patients and healthcare providers to benefit from our expertise in this area," said Raman Singh, chief executive officer, Mundipharma.
Riccardo Braglia, vice chairman and chief executive officer, Helsinn Group, said, "Helsinn and Mundipharma have an effective, longstanding partnership and Mundipharma successfully markets, promotes and distributes a number of our products across a range of territories. We're delighted to be able to extend this relationship through this agreement."